<DOC>
	<DOCNO>NCT00244634</DOCNO>
	<brief_summary>Study 261A dose-ranging safety study candesartan cilexetil . It multinational , multicenter , randomize , double-blind , placebo-controlled , parallel-group study 4 week treatment period hypertensive pediatric subject . Subjects undergo screen evaluation , 1-week , single-blind , placebo run-in eligible subject allocate receive 1 3 dose level candesartan cilexetil placebo . The study include 2 panel base subject weight . The primary efficacy analysis base intent-to-treat population test slope = 0 linear regression model change sit systolic blood pressure dependent non-zero dose pool across weight panel independent variable . For subject without Double-Blind Week 4 blood pressure determination , carry last value forward assign value . Additional analysis include data pool similar dose range study conduct child 1 &lt; 6 year age .</brief_summary>
	<brief_title>Atacand Dose Range Finding Study Pediatric Subjects 6 &lt; 17 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Male female age 6 &lt; 17 yearsofage parent guardian 's signing informed consent . Subjects hypertension either : Diagnosed untreated mean sit systolic and/or diastolic blood pressure ≥ 95th percentile ≤ 20 mm Hg ( systolic ) and/or 10 mm Hg ( diastolic ) 95th percentile randomisation base heightadjusted chart age gender ; Previously diagnose currently treat mean sit systolic blood pressure and/or diastolic blood pressure ≥ 95th percentile ≤ 20 mm Hg ( systolic ) and/or 10 mm Hg ( diastolic ) 95th percentile randomisation ( treatment ) base heightadjusted chart age gender . Females childbearing potential ( postmenarche ) must negative urine pregnancy test prior randomization adhere pregnancy prevention method ( abstinence , barrier method plus spermicidal foam , oral , implanted contraceptive ) . A sign informed consent parent legal guardian assent form sign subject ( applicable ) . Any situation , clinical condition laboratory abnormality , opinion investigator sponsor , may interfere subject 's participation study would pose significant risk subject interfere assessment safety efficacy endpoint . Hypertension secondary coarctation aorta , pheochromocytoma , hyperthyroidism , Cushing 's syndrome , medication ( eg : corticosteroid ) . Known history bilateral renal artery stenosis , unilateral renal artery stenosis renal transplant . Glomerular filtration rate &lt; 50 mL/min base estimate value use Schwartz Formula . Nephrotic syndrome remission . Insulin dependent diabetes mellitus . Known bleeding , coagulation , platelet disorder could interfere blood sampling . Clinically significant valvular heart disease . Clinical diagnosis heart failure . Clinically significant arrhythmia ( eg , arrhythmia require medical therapy cause symptom ) . Second third degree AV block . Pregnant breastfeeding infant . Impaired liver function define either acute liver disease chronic liver disease persistent liver enzyme value great 1½ time upper limit reference range AST ALT . Known hypersensitivity ARBs . Unable antihypertensive medication ( diuretic , beta blocker , ACE Inhibitors , etc ) 6weeks . Inability discontinue medication may contribute elevate blood pressure e.g . systemic corticosteroid . Currently use , use within 14 day prior receive doubleblind medication , concomitant medication opinion investigator could negatively affect subject . Unable unwilling comply study requirement include blood sample swallow study drug tablet . Received investigational agent within 30 day prior receive study medication . Alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>